Key Developments: Xenoport Inc (XNPT.O)

XNPT.O on Nasdaq

6.91USD
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$6.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
365,245
52-wk High
$7.20
52-wk Low
$3.14

Search Stocks

Latest Key Developments (Source: Significant Developments)

XenoPort and the NIAAA announce clinical trial agreement to study HORIZANT as a potential treatment for alcohol use disorder
Tuesday, 9 Sep 2014 08:30am EDT 

XenoPort Inc:Enters into an agreement to conduct a clinical trial of HORIZANT Extended-Release Tablets as a potential treatment for alcohol use disorder.Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT.  Full Article

XenoPort Inc announces Initiation of a Phase 2 Clinical Trial of XP23829
Monday, 23 Jun 2014 08:30am EDT 

XenoPort Inc:Initiated a Phase 2 clinical trial of XP23829.The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.  Full Article

XenoPort Inc announces pricing of public offering of common stock
Thursday, 23 Jan 2014 11:30pm EST 

XenoPort Inc:Says the pricing of an underwritten registered public offering of 12,000,000 shares of its common stock at a price to the public of $6.00 per share.Says the size of the offering was increased from the 10,000,000 shares previously announced.Says it has also granted to the underwriters a 30 day option to purchase up to an additional 1,800,000 shares of its common stock.Says the offering is expected to close on or about Jan. 29, 2014.Says Credit Suisse Securities (USA) LLC is acting as sole book-running manager for the offering.Says RBC Capital Markets, LLC and Wells Fargo Securities, LLC are acting as co-managers.  Full Article

XenoPort Inc announces proposed public offering of common stock
Tuesday, 21 Jan 2014 06:10am EST 

XenoPort Inc:Says it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering.Says XenoPort also intends to grant the underwriters a 30-day option to purchase up to a maximum of 1,500,000 additional shares of common stock.Says all of the shares in the proposed public offering are to be sold by XenoPort.Says Credit Suisse Securities (USA) LLC is acting as sole book-running manager for the offering. RBC Capital Markets, LLC and Wells Fargo Securities, LLC are acting as co-managers.  Full Article

XenoPort Inc Announces Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients
Monday, 20 May 2013 06:30am EDT 

XenoPort Inc announced top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the treatment of patients with spasticity due to multiple sclerosis (MS). The trial was unsuccessful in demonstrating that AP provided statistically significant improvement relative to placebo in the co-primary endpoints of the study. The trial was a 13-week, multicenter, randomized, double-blind, placebo-controlled study that enrolled 228 subjects in 30 sites in the United States. There was a one-week placebo run-in period, two weeks of up-titration, eight weeks at the maintenance dose and two weeks of down-titration. Eligible subjects were randomized to one of four arms: 15 mg, 30 mg or 45 mg of AP or placebo dosed twice a day (BID) with food. The first of the co-primary endpoints for the study was the time-matched change from baseline in Maximum Ashworth score (six hours post-dose time point) at the end of the maintenance dose period. The muscle group in the lower limbs with the highest Ashworth score at baseline was followed throughout the trial. Subjects entering the trial were required to have a Maximum Ashworth score of two or greater prior to entering the study and at the end of the placebo run-in period, which served as baseline. The second co-primary endpoint was the score on the 7-point Patient Global Impression of Change scale at the end of the maintenance period.  Full Article

Search Stocks